January 26, 2015 8:16 PM ET

Company Overview of The Multiple Myeloma Research Foundation, Inc

Company Overview


United States

Founded in 1998

Key Executives for The Multiple Myeloma Research Foundation, Inc

Chief Executive Officer
Age: 49
Founder and Executive Chairman
Age: 55
Age: 59
Vice President of Communications
Chief Development and Marketing Officer
Compensation as of Fiscal Year 2014.

The Multiple Myeloma Research Foundation, Inc Key Developments

The Multiple Myeloma Research Foundation and GNS Healthcare Announce Collaboration to Identify Potential New Multiple Myeloma Therapies

GNS Healthcare announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma. The effort will combine the unprecedented genomic and clinical data from the MMRF's CoMMpass Study with revolutionary GNS machine learning platforms and rapid computer simulations. The work supports the development of computer models of myeloma disease that may uncover novel molecular pathways that can prevent progression of disease and address the unmet treatment needs of patients with multiple myeloma. CoMMpass is a longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma. Its objective is to map each of these patients genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments. GNS will use an in silico process, applying its MAX architecture and patented REFS inference engine and simulation platforms to the CoMMpass data. REFS will identify causal drivers and underlying molecular processes of disease progression. REFS will also discover the most likely targets for therapeutics to treat, and perhaps to predict and prevent, relapses and refractory disease. REFS will also discover predictive diagnostic biomarkers that determine which treatments will work and for which patients. The work promises to support physicians and patients with a broader set of individualized treatment protocols mapped to specific molecular and genomic characteristics. GNS has used REFS successfully to advance the research priorities of numerous nonprofit organizations focused on diseases including Huntington’s disease, multiple sclerosis, childhood asthma, Alzheimer's disease and others. Its work ultimately enables next-generation care management solutions focused on reducing adverse events, slowing disease progression and improving therapeutic effectiveness through precision medicine.

Multiple Myeloma Research Foundation Announces New Initiative to Accelerate Development of Targeted Therapies for Multiple Myeloma with Food and Drug Administration (FDA) and National Cancer Institute

The Multiple Myeloma Research Foundation announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM). The MMRF, in collaboration with the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), pharmaceutical, biotech and diagnostic industry members, academic center leaders and patients, initiated the formal development of a Master Protocol to allow patients to participate in clinical trials evaluating several investigational therapies at once. Complementing the pursuit of novel drug classes and immunotherapies in MM drug development is the promise of identifying new targeted therapies for patients with specific genetic alterations. The MM Master Protocol would enable several, Phase II clinical trials to take place in parallel within a single study design. Patients would be assigned to an appropriate experimental therapy based on an analysis of their genetic alterations. This novel approach, which has recently been applied in other cancers, allows multiple new therapies to be evaluated more rapidly than with a traditional trial design. Decisions to advance an investigational drug to Phase III testing in a specific genetic subgroup, or to test a different drug in this subgroup, can be expedited -- with the goal of getting new drugs to patients faster than ever before. In addition to discussing protocol design, meeting participants addressed the application of minimal residual disease (MRD) measurements as surrogate endpoints for MM clinical trials. Multiple reports suggest that MRD is a strong predictor of long-term progression free survival (PFS) in multiple myeloma.

The Multiple Myeloma Research Foundation, Inc Presents at The Economist Health Care Forum, Sep-17-2014 11:45 AM

The Multiple Myeloma Research Foundation, Inc Presents at The Economist Health Care Forum, Sep-17-2014 11:45 AM. Venue: Seaport Boston Hotel, 1 Seaport Lane, Boston, MA 02210, United States. Speakers: Walter M. Capone, Chief Executive Officer, President and Chief Operating Officer.

Similar Private Companies By Industry

Company Name Region
Fox Imports, LLC United States
Bluewave Computing LLC United States
Tokio Marine Specialty Insurance Co. United States
One Source Printing and Graphics, Inc. United States
Infra-Metals Co. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Multiple Myeloma Research Foundation, Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.